Homepage

Insmed Incorporated

INSM NASDAQ Categories PDF
Healthcare · Biotechnology · United States · Updated May 10, 5:11pm
$101.30
Price
$22.0B
Market Cap
1,271
Employees
0.89
Beta
William H. Lewis
CEO
Business Description

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Business History
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
Period Revenue Net Income Net Margin YoY/QoQ
Key Metrics
API Direct from provider CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALC
Stock Price / EPS (Diluted)
-15.80
Stock Price: $101.30
EPS (Diluted): -6.41
P/B Ratio (Price vs net asset value)
API
Stock Price / Book Value Per Share
50.31
Stock Price: $101.30
Total Equity: $738.98M
Shares: 213,637,000
EV/EBITDA (Total value vs operating profit)
API
Enterprise Value / EBITDA
-31.96
Market Cap: $21.96B
Total Debt: $735.27M
Cash: $510.45M
EBITDA: -$1.17B
Enterprise Value (Takeover price (cap + debt - cash))
API
Market Cap + Total Debt - Cash
$37.4B
Market Cap: $21.96B
Total Debt: $735.27M
Cash: $510.45M
Gross Margin (Revenue left after direct costs)
API
Gross Profit / Revenue
79.4%
Gross Profit: $481.55M
Revenue: $606.42M
Operating Margin (Revenue left after all operations)
API
Operating Income / Revenue
-194.0%
Operating Income: -$1.18B
Revenue: $606.42M
Net Margin (Revenue left as actual profit)
API
Net Income / Revenue
-210.5%
Net Income: -$1.28B
Revenue: $606.42M
ROE (Profit from shareholder equity)
CALC
Net Income / Total Equity
-172.8%
Net Income: -$1.28B
Total Equity: $738.98M
ROIC (Profit from all invested capital)
CALC
NOPAT / Invested Capital
-122.6%
Operating Income: -$1.18B
Tax Rate: -0.4%
Equity: $738.98M
Total Debt: $735.27M
Cash: $510.45M
Current Ratio (Can it pay short-term bills)
API
Current Assets / Current Liabilities
3.83
Current Assets: $1.79B
Current Liabilities: $468.87M
Debt/Equity (Leverage — debt vs equity)
CALC
Total Debt / Total Equity
0.99
Short-Term Debt: $19.26M
Long-Term Debt: $716.00M
Total Debt: $735.27M
Total Equity: $738.98M
Rev/Share (Top-line per share)
CALC
Revenue / Shares Outstanding
$2.84
Revenue: $606.42M
Shares: 213,637,000
Book Value/Share (Net assets per share)
CALC
(Total Assets - Total Liabilities) / Shares
$3.46
Total Equity: $738.98M
Shares: 213,637,000
FCF/Share (Real cash generated per share)
CALC
(Operating Cash Flow + CapEx) / Shares
$-4.53
Operating CF: -$935.01M
CapEx: -$32.56M
Shares: 213,637,000
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
API
Last Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $101.30
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$1.28B
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares INSM against LLM-researched typical ranges for its industry. One research call per industry, cached indefinitely — every stock in the same industry reuses the same baseline.
Deep Analysis

Pre-flight intelligence scans the company first, then routes to the right analytical methods.

0 Company Classification — What type of company is this?
1 Industry Landscape — Where is the industry headed?
2 Company Momentum — Where is this company trending?
3 Forward Projection — 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a DCF Valuation — Present value of future cash flows
4b Earnings Power Value — Floor value — worth with zero growth
4c Anchored PE — Industry PE adjusted for growth differential
4d Reverse DCF — What growth is the market pricing in?
4e Revenue-Based DCF — For growth/narrative companies (skip if mature earner)
4f Anchored P/S — Price-to-Sales peer comparison (skip if mature earner)
4g Scenario Analysis — Bull / Base / Bear (skip if mature earner)
4h Dividend Discount Model — For dividend/income stocks only
4i Book Value Analysis — For deep value / turnaround stocks only
4j Insider Activity — Are insiders buying or selling?
4f Cash Flow Quality — How trustworthy is the FCF?
4g Debt Maturity Risk — Can it handle its debt?
4h Macro Environment — Rates, market valuation, volatility
4i Sector Intelligence — How does this company compare within its sector?
4j Revenue Confidence — How reliable is the growth projection?
4k Sensitivity Analysis — How fragile is the fair value estimate?
4l Sector Demand Cycle — Is the sector in a boom, steady state, or contraction?
5 AI Investigation — Adaptive research engine (Claude)
5b Thesis Evaluation — What does the market believe? (narrative/platform stocks only)
6 Valuation Synthesis — Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Metric 2021 2022 2023 2024 2025
Revenue $188.5M $245.4M $305.2M $363.7M $606.4M
Cost of Revenue $44.2M $55.1M $65.6M $85.7M $124.9M
Gross Profit $144.3M $190.2M $239.6M $278.0M $481.5M
Operating Expenses $519.4M $647.6M $949.3M $1.2B $1.7B
Operating Income -$375.1M -$457.3M -$709.6M -$878.3M -$1.2B
Net Income -$434.7M -$481.5M -$749.6M -$913.8M -$1.3B
EBITDA -$383.6M -$447.4M -$660.2M -$818.8M -$1.2B
EPS $-3.88 $-3.91 $-5.34 $-5.57 $-6.41
EPS (Diluted) — — — — —
Balance Sheet (Annual)
Metric 2021 2022 2023 2024 2025
Cash & Equivalents $716.8M $1.1B $482.4M $555.0M $510.4M
Total Current Assets $837.0M $1.3B $929.1M $1.6B $1.8B
Total Assets $1.2B $1.7B $1.3B $2.0B $2.3B
Current Liabilities $135.2M $190.2M $225.6M $297.5M $468.9M
Long-Term Debt $566.6M $1.1B $1.2B $1.3B $716.0M
Total Liabilities $833.0M $1.6B $1.7B $1.7B $1.5B
Total Equity $410.5M $88.0M -$331.9M $285.4M $739.0M
Retained Earnings -$2.3B -$2.7B -$3.4B -$4.4B -$5.6B
Cash Flow (Annual)
Metric 2021 2022 2023 2024 2025
Operating Cash Flow -$363.3M -$400.4M -$536.2M -$683.9M -$935.0M
Capital Expenditure -$7.3M -$9.9M -$13.3M -$21.9M -$32.6M
Free Cash Flow -$370.6M -$410.3M -$549.5M -$705.8M -$967.6M
Acquisitions (net) -$6.7M $24.7M $3.4M $0 $0
Debt Repayment — — — — —
Dividends Paid — — — — —
Stock Buybacks $0 $0 $0 $0 $0
Net Change in Cash $184.0M $357.3M -$591.7M $72.7M -$44.6M
Analyst Estimates (Annual)
Metric 2027 2028 2029 2030
Revenue $2.8B
$2.4B – $3.0B
 $3.8B
$3.7B – $3.9B
 $5.1B
$4.4B – $6.1B
 $6.4B
$5.6B – $7.6B
EBITDA -$2.8B
-$3.0B – -$2.4B
 -$3.8B
-$3.9B – -$3.7B
 -$5.1B
-$6.1B – -$4.4B
 -$6.4B
-$7.6B – -$5.6B
Net Income $84.7M
-$49.9M – $219.4M
 $1.0B
$299.3M – $1.3B
 $1.7B
$1.4B – $2.1B
 $2.3B
$1.9B – $2.9B
EPS — — — —
Growth Trends (YoY %)
Metric 2022 2023 2024 2025
Revenue Growth +30.2% +24.4% +19.2% +66.7%
Gross Profit Growth +31.8% +26.0% +16.0% +73.2%
Operating Income Growth -21.9% -55.2% -23.8% -34.0%
Net Income Growth -10.8% -55.7% -21.9% -39.7%
EBITDA Growth -16.6% -47.6% -24.0% -43.1%
Community AI Feedback
Sign in to Contribute
No community reviews yet for INSM. Be the first — export the analysis to your AI and contribute back.
My Notes personal — only you see this
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.193 · 1946f027 · 2026-05-08 18:57:27